title: Joint hypermobility syndrome: a risk factor for fixed dystonia?
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Kassavetis
authors.forename: Amit
authors.initials: A
authors.lastname: Batla
authors.forename: Isabel
authors.initials: I
authors.lastname: Pareés
authors.forename: Tabish A
authors.initials: TA
authors.lastname: Saifee
authors.forename: Anette
authors.initials: A
authors.lastname: Schrag
authors.forename: Carla
authors.initials: C
authors.lastname: Cordivari
authors.forename: Kailash P
authors.initials: KP
authors.lastname: Bhatia
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Edwards
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000627:therapeutic use; D004421:Dystonia / Q000188:drug therapy / Q000209:etiology*; D004535:Ehlers-Danlos Syndrome / Q000150:complications*; D005260:Female; D006801:Humans; D007593:Joint Instability / Q000151:congenital; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D055815:Young Adult
chemical_list: D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins